An explainable imaging-clinical biomarker for non-small cell lung cancer prognostication based on normalised hotspot to centroid distance and [18F]FDG PET/CT radiomics
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07659-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Mitchell Chen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK. d.mitch.chen@gmail.com. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Fluorodeoxyglucose F18. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIHR Imperial Biomedical Research Centre, Medical Research Council.
Abstract (Originalsprache)
Purpose
Accurate prognostication is crucial for guiding personalised treatment strategies in non-small cell lung cancer (NSCLC). While radiomics offers promise, few features are derived from cancer models with causal justification to support their biological validity. This study evaluated the prognostic utility of normalised hotspot-to-centroid distance (NHOC), a recently proposed [18F]FDG PET imaging metric derived from a cancer evolutionary model, and its integration with PET/CT radiomics and clinical features to form a composite signature, non-invasive lung cancer evolution vector (nLCEV).
Methods
A retrospective, multi-centre study was conducted using pre-treatment [18F]FDG PET/CT scans from 285 NSCLC patients (mean age: 67.7 ± 10.1 years; male:female = 171:114, International Association for the Study of Lung Cancer stage: T1/2/3/4/unknown = 61/118/53/52/1, N0/1/2/3/unknown = 133/46/71/34/1, M0/1/unknown = 222/62/1) from Imperial College Healthcare NHS Trust as the discovery cohort. External validation cohorts included patients from King’s College ( n = 53), Royal Marsden ( n = 63), Mount Vernon ( n = 61), and Nottingham University ( n = 38) hospitals. NHOC was evaluated for 3-year overall survival prediction and combined with a multi-regional PET/CT radiomics predictive vector (RPV) and disease stage to develop nLCEV.
Results
NHOC and RPV demonstrated independent prognostic value (hazard ratio (HR) [95% confidence interval]: 2.52 [1.60–3.98] and 2.68 [2.13–3.38], respectively). nLCEV achieved an area under the receiver operating characteristic curve of 0.76 [0.60–0.92] and stratified patients into high- and low-risk groups across all validation cohorts with significant HR: KCL 3.27 [1.31, 8.16], Marsden 2.21 [1.02, 4.78], Mount Vernon 2.60 [1.42, 4.76], and Nottingham 4.14 [1.44, 11.90] (all p < 0.05).
Conclusion
NHOC enhances NSCLC patient survival prediction, and when integrated with PET-CT radiomics and disease stage, offers a robust, non-invasive approach to disease prognostication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK. d.mitch.chen@gmail.com.
- Department of Radiology & Nuclear Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. d.mitch.chen@gmail.com.
- Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, W12 0NN, UK.
- Department of Radiology & Nuclear Medicine, Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK.
- Institute of Nuclear Medicine, University College London, London, NW1 2BU, UK.
- North West London Pathology, Charing Cross Hospital, London, W6 8RF, UK.
ORCID-Profile: Mitchell Chen
Förderung
- NIHR Imperial Biomedical Research Centre
- Medical Research Council
Zitieren
APA
Chen, M., Copley, S. J., Han, Y., Arshad, M. A., Viola, P., Linton-Reid, K., Stoycheva, T., Cook, G. J. R., Landau, D., Chua, S., O'Connor, R., Dickson, J., Power, D., Rockall, A. G., Barwick, T. D., & Aboagye, E. O. (2025). An explainable imaging-clinical biomarker for non-small cell lung cancer prognostication based on normalised hotspot to centroid distance and [18F]FDG PET/CT radiomics. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07659-4
Vancouver
Chen M, Copley SJ, Han Y, Arshad MA, Viola P, Linton-Reid K, et al. An explainable imaging-clinical biomarker for non-small cell lung cancer prognostication based on normalised hotspot to centroid distance and [18F]FDG PET/CT radiomics. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07659-4
BibTeX
@article{Chen2025,
author = {Chen, Mitchell and Copley, Susan J and Han, Yidong and Arshad, Mubarik A and Viola, Patrizia and Linton-Reid, Kristofer and Stoycheva, Tina and Cook, Gary J R and Landau, David and Chua, Sue and O'Connor, Richard and Dickson, Jeannette and Power, Danielle and Rockall, Andrea G and Barwick, Tara D and Aboagye, Eric O},
title = {An explainable imaging-clinical biomarker for non-small cell lung cancer prognostication based on normalised hotspot to centroid distance and [18F]FDG PET/CT radiomics},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07659-4}
}
EUVIMED